RIGEL PHARMACEUTICALS INC (RIGL)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$24.5M
Cash & Equivalents
$2.7M
Quarterly Burn Rate
$545M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06445959 Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib PHASE2 Recruiting 78

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for RIGL.

SEC EDGAR Filings

All SEC filings for RIGEL PHARMACEUTICALS INC on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.